Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Endokrynol Pol. 2024;75(2):207-215. doi: 10.5603/ep.98765. Epub 2024 Apr 22.
Control attenuation parameters (CAP) can detect nonalcoholic fatty liver disease (NAFLD). Our previous study found that miR-192-5p could screen for acute pancreatitis (AP) in NAFLD patients. This study focused on the role of CAP and miR-192-5p in NAFLD of acute AP.
AP patients and controls were enrolled. Classification of AP patients into NAFLD/AP patients and non-NAFLD/AP was made based on the CAP value. CAP was measured by liver transient elastography. Serum miR-192-5p was measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Logistic regression analysis was conducted to examine the risk factors for the development of NAFLD. Receiver operating characteristic (ROC) was assessed for the predictive value of AP severity.
NAFLD was more common in the AP group than in the controls (35.00% vs. 8.75%). The CAP value was higher in AP patients with NAFLD than in non-NAFLD, whereas miR-192-5p was significantly lower in AP patients with NAFLD. Additionally, AP patients with NALFD are more likely to experience respiratory failure, systemic inflammatory response syndrome (SIRS), and pancreatic necrosis with longer hospitalisation and exacerbate the incidence of moderate to severe AP. Both miR-192-5p and TG are potential risk factors for the development of NAFLD in patients with AP. Furthermore, the CAP value gradually increased with increasing AP severity, while miR-192-5p gradually decreased. Finally, the sensitivity and specificity of CAP combined with miR-192-5p for the prediction of moderate to severe AP were scored as 82.61% and 82.43%, respectively.
NAFLD exacerbated the progression of AP, and CAP combined with miR-192-5p could predict the severity of AP. Our study may provide more reference for AP disease progression and treatment.
控制衰减参数(CAP)可用于检测非酒精性脂肪性肝病(NAFLD)。我们之前的研究发现,miR-192-5p 可用于筛选非酒精性脂肪性肝病患者中的急性胰腺炎(AP)。本研究主要关注 CAP 和 miR-192-5p 在非酒精性脂肪性肝病合并急性 AP 中的作用。
纳入 AP 患者和对照者。根据 CAP 值将 AP 患者分为非酒精性脂肪性肝病/AP 患者和非非酒精性脂肪性肝病/AP 患者。通过肝脏瞬时弹性成像测量 CAP。通过逆转录定量聚合酶链反应(RT-qPCR)测量血清 miR-192-5p。采用 logistic 回归分析探讨非酒精性脂肪性肝病发生的危险因素。评估受试者工作特征(ROC)曲线评估 AP 严重程度的预测价值。
AP 组中 NAFLD 更为常见(35.00% vs. 8.75%)。与非非酒精性脂肪性肝病患者相比,非酒精性脂肪性肝病合并 AP 患者的 CAP 值更高,而 miR-192-5p 水平则明显更低。此外,非酒精性脂肪性肝病合并 AP 患者更易发生呼吸衰竭、全身炎症反应综合征(SIRS)和胰腺坏死,住院时间更长,且更易发生中重度 AP。miR-192-5p 和 TG 均为 AP 患者发生非酒精性脂肪性肝病的潜在危险因素。此外,CAP 值随 AP 严重程度的增加而逐渐升高,而 miR-192-5p 则逐渐降低。最后,CAP 值联合 miR-192-5p 预测中重度 AP 的灵敏度和特异度分别为 82.61%和 82.43%。
非酒精性脂肪性肝病加重了 AP 的进展,而 CAP 联合 miR-192-5p 可预测 AP 的严重程度。本研究可能为 AP 疾病进展和治疗提供更多参考。